Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 169, Issue 1, Pages 77-80Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.13262
Keywords
momelotinib; neuropathy; myelofibrosis; myeloproliferative
Categories
Funding
- Gilead
Ask authors/readers for more resources
Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32weeks and duration 11months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P=002) and longer survival (P=0048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available